AP-2δ Inhibitors
Chemical inhibitors of AP-2δ encompass various compounds that target specific signaling pathways implicated in the functional regulation of this transcription factor. PD 98059 and U0126 are both inhibitors of MEK, a kinase within the MAPK/ERK pathway. The inhibition of this pathway can reduce the phosphorylation and activation of AP-2δ, potentially leading to a decrease in its transcriptional activity. LY294002 and Wortmannin are inhibitors of PI3K, and by inhibiting this kinase, they disrupt the PI3K/AKT pathway. This disruption can in turn decrease the phosphorylation events or protein-protein interactions necessary for the optimal function of AP-2δ. Similarly, SP600125 targets the JNK signaling pathway, which can interfere with the regulatory mechanisms of AP-2δ, especially in responses to cellular stress or differentiation.
In addition to these, SB203580 inhibits the p38 MAPK, which can affect AP-2δ activity by limiting the activation of associated transcription factors or coactivators that are involved in the same response pathways as AP-2δ. Rapamycin, an mTOR inhibitor, can lead to reduced protein synthesis and affect proteins that are regulated by mTOR signaling, which could include AP-2δ, altering its activity due to changes in protein translation or degradation. KN-93 inhibits CaMKII, potentially impacting calcium signaling pathways that alter the phosphorylation state of AP-2δ. Bisindolylmaleimide I, Chelerythrine, and Go6983 all inhibit PKC, which can affect pathways that regulate transcription factors, including AP-2δ, potentially diminishing its DNA-binding capability or its interaction with regulatory proteins. NF449, a potent Gs-alpha subunit inhibitor, can alter cAMP-dependent pathways, potentially modifying AP-2δ's interaction with cAMP response element-binding proteins or coactivators involved in cellular signaling, leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which is part of the MAPK/ERK pathway. AP-2δ is a transcription factor potentially regulated by this pathway; inhibition of MEK can reduce AP-2δ activity by limiting its phosphorylation and activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor which can lead to reduced activation of AKT, downstream of which AP-2δ may be regulated. Inhibition of PI3K can decrease AP-2δ activity by reducing critical phosphorylation events or protein-protein interactions necessary for its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that can interfere with AP-2δ activity by inhibiting the JNK signaling pathway, which could be involved in the regulation or activity of AP-2δ, particularly in stress response or cellular differentiation contexts. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, potentially affecting AP-2δ by limiting activation of transcription factors or coactivators that are involved in the same cellular response pathways as AP-2δ. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
By inhibiting PI3K, it can disrupt the PI3K/AKT pathway, which may be involved in the post-translational modification of AP-2δ, leading to diminished protein activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, which can lead to reduced protein synthesis and affect proteins regulated by mTOR signaling, including possible effects on AP-2δ activity due to altered protein translation or degradation. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
Inhibits CaMKII, which can affect calcium signaling pathways that may impact the activity of AP-2δ by altering its phosphorylation state or interaction with coactivators. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Inhibits PKC, which can affect signaling pathways that regulate transcription factors including AP-2δ, potentially reducing its DNA-binding capability or interaction with other regulatory proteins. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
A potent Gs-alpha subunit inhibitor, which can alter cAMP-dependent signaling pathways, potentially affecting AP-2δ by modifying its interaction with cAMP response element-binding (CREB) proteins or coactivators in signal transduction. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
A PKC inhibitor that may prevent AP-2δ from achieving full activity by disrupting PKC-mediated phosphorylation processes or the activation of pathways that involve AP-2δ. | ||||||